Summary: Apollo Health has unveiled the BrainScan Alzheimer’s disease test through Neurocode, which uses three blood tests to detect Alzheimer’s pathology, offering a less invasive and more accessible alternative to traditional methods. Key Takeaways:. Innovative Testing Method: The BrainScan test includes the high-sensitivity p-tau217 test and other neurological...

New Alzheimer’s Blood Test Available to Consumers

The Mirror US

Although there is currently no known cure for Alzheimer's, there are treatments that can lessen its symptoms, including disorientation and memory loss, and some may even stop the disease's progression

New Alzheimer's treatment could reverse brain disease and restore memory, study finds

Queen City News

A blood test can determine whether memory loss is caused by Alzheimer’s disease with more than 90 percent accuracy, according to a new study published Sunday.

Blood test has a 90 percent accuracy rate in determining whether memory loss is due to Alzheimer’s: Study

The Associated Press

WASHINGTON (AP) — New blood tests could help doctors diagnose Alzheimer’s disease faster and more accurately, researchers reported Sunday – but some appear to work far better than others. It’s tricky to tell if memory problems are caused by Alzheimer’s. That requires confirming one of the disease’s...

Blood tests for Alzheimer’s may be coming to your doctor’s office. Here’s what to know

Researchers at the Mayo Clinic have drafted new criteria for a memory-loss disorder that bears similarities with Alzheimer's yet has a better prognosis. The corresponding article was published in Brain Communications. "This research creates a precise framework that other medical professionals can use to care for their patients. It has...

New Memory Loss Disorder that Mimics Alzheimer's Identified

Minnesota State

Fox News

Scientists at Mayo Clinic say they have identified a new type of memory loss that is very similar to Alzheimer’s disease, but doesn’t progress as quickly and has a “better prognosis."

Mayo Clinic finds new type of memory loss that’s often mistaken for Alzheimer’s

Positive trial results show the specialized cell product achieved an overall slowing of disease worsening compared to placebo. Lomecel-B, a living cell product for the treatment of Alzheimer’s Disease, has met key primary and secondary endpoints in the Phase IIa CLEAR MIND clinical trial (NCT05233774). Among emerging, positive results from the study, Longeveron’s potential therapy showed an overall slowing of disease worsening compared to placebo.1.

Lomecel-B Meets Key Objectives in Phase IIa Alzheimer’s Study

New York City, NY

Writers represent independent, third-party users who have joined our contributor program and self-verified their accounts. Writers are expected, like all users, to adhere to our Community Standards.

writer

Cheryl E Preston

Yesterday was the third time this year that an ad stating Chelsea Clinton lives in a beautiful Virginia home popped up on my laptop. My computer did not warn me this was a dangerous site, so this time, I clicked on the link.

Chelsea Clinton is rumored to be living in Virginia but probably still in NYC

Researchers at Mayo Clinic have established new criteria for a memory-loss syndrome in older adults that speciﬁcally impacts the brain's limbic system. It can often be mistaken for Alzheimer disease. However, limbic-predominant Amnestic Neurodegenerative Syndrome, or LANS, progresses more slowly and has a better prognosis, and is now more clearly deﬁned for doctors working to ﬁnd answers for memory loss patients.

Mayo Clinic Researchers Define New Memory Loss Syndrome

Blood tests that can detect 90% of Alzheimer’s cases could revolutionize access to Alzheimer’s treatment, studies say.

Alzheimer’s blood test catches 90% of early dementia cases, study finds

Recent advancements in medical research are paving the way for blood tests that could significantly improve the early diagnosis of Alzheimer's disease. These innovative tests have the potential to make detecting the disease faster, less invasive, and more accessible compared to traditional methods. A recent study conducted in Sweden has...

Revolutionary Blood Tests for Alzheimer’s: A Breakthrough in Early Diagnosis

Fareeha Arshad

The most extensive study of its kind, analyzing data from 273,260 female participants in the UK Biobank, suggests that the timing of menstruation and menopause could influence the risk of developing dementia later in life. Researchers from University College London found that individuals with a longer reproductive span—measured from the onset of menstruation to menopause—had a decreased risk of dementia. Those who menstruated for 34 to 37 years showed a 28 per cent reduced risk compared to those with a shorter reproductive span.

Longer Reproductive Span Linked to Lower Dementia Risk in Women Study Finds

Two recent developments in Alzheimer’s disease research offer new hope for patients living with the disease, and their families. Among those, in June, Tiziana Life Sciences received Food and Drug Administration clearance to use intranasal foralumab in its first patient with moderate Alzheimer’s disease under the FDA’s expanded access investigational new drug program.

FDA clears nasal spray for moderate Alzheimer’s disease in first patient

USA TODAY

A new generation of blood tests could accelerate Alzheimer's diagnosis and improve treatment for millions of older Americans.

How a new blood test technology could change Alzheimer's treatment forever

Medical News Today

Researchers have found unique molecular changes in the blood-brain barrier of people with Alzheimer’s disease, markers of which can be detected in the blood.

Study identifies Alzheimer's biomarkers linked to blood vessel changes in the brain

Spinal muscular atrophy (SMA) is a severe neurological disease for which there is presently no cure, although current therapies can alleviate symptoms. In the search for better treatment options, scientists at DZNE and the Dresden University of Technology are now drawing attention to previously unnoticed abnormalities in embryonic development. They base their argument on studies of so-called organoids: Laboratory-grown tissue cultures that can reconstruct disease processes. Their findings are published in the journal “Cell Reports Medicine”.

Embryonic Abnormalities in SMA May Lead to New Therapies

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

India Currents

My article last month described dementia, its causes and prevalence, and its tell-tale signs. There is no cure at present for the debilitating and progressive disease. However, its early diagnosis enables us to develop a care plan in coordination with specialists and experts, for a better prognosis and improved quality of life for patients, caregivers, and their loved ones.

Can You Reduce The Risk Of Dementia?

ScienceAlert


Researchers have discovered patterns in the brain that reflect the effectiveness of deep brain stimulation therapy for obsessive–compulsive disorder (OCD), potentially leading to improvements in the way that the condition is handled individually for each case.



					
			

A team led by researchers from the Baylor College of Medicine in Texas used brain scans from 12 people with treatment-resistant OCD, who were undergoing deep brain stimulation (DBS) – a treatment that monitors and controls the activity of precise patches of neural tissue via implanted electrodes.
"Recent advances in surgical neuromodulation have enabled long-term continuous monitoring of brain activity in OCD patients during their everyday...

The Neural Signature of OCD Has Been Identified in The Human Brain

Variations in certain genes can modify the risk of developing Alzheimer’s disease (AD) and other types of dementia. Some of the best understood variants to date are in a gene called APOE. This gene plays a role in the transport of cholesterol and other fatty molecules in the brain and body. People with a variant of APOE called APOE4 have an increased risk of developing AD dementia. In contrast, people with a variant called APOE2 appear to have some protection against developing dementia.

Gene variant slows form of inherited Alzheimer’s disease

A blood test has been shown to detect Alzheimer’s disease in health care settings with up to 90% accuracy, as researchers presented at the Alzheimer’s Association International Conference.

Alzheimer’s blood test detects disease with 90% accuracy in routine doctors’ appointments: study

NewsBreak

Blood Test Identifies Alzheimer’s With 90% Accuracy

As highly accurate blood tests for Alzheimer’s disease are moving closer to use in physician’s offices, new research suggests that they may revolutionize the accuracy of...

Blood Test Identifies Alzheimer’s With 90% Accuracy

Comments / 0